Estelle

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Estelle

What is Estelle? Overview and Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Levonorgestrel
Form Tablet (Oral Contraceptive Pill)
Pharmacological Class Systemic Hormonal Contraceptive (ATC G03AA)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic Hormonal Compounds

What Type of Medicine is Estelle (Ethinyl Estradiol/Levonorgestrel)?

Estelle is a trade name for a Combined Hormonal Contraceptive (CHC), commonly known as an Oral Contraceptive Pill (OCP). This drug is a fixed combination product that falls under the systemic hormonal contraceptive class, categorized under the WHO ATC code G03AA. Its primary purpose is the highly effective prevention of pregnancy (contraception). Pharmacological studies and extensive clinical application have clinically recognized this specific fixed combination of estrogen and progestogen as a primary and highly reliable method of birth control.


Compositional Basis: Synthetic Estrogen and Progestogen

The foundation of the medication lies in its two active ingredients: Ethinyl Estradiol and Levonorgestrel. These are both synthetic hormonal compounds, designed to mimic the actions of naturally occurring estrogen and progesterone. Ethinyl Estradiol is a synthetic estrogen analogue, while Levonorgestrel is a potent synthetic progestogen derived from the 19-nortestosterone class. The presence of both hormone types ensures the comprehensive management of the hormonal cycle required for birth control. This combination is delivered as a small, compressed tablet, which establishes the oral route of administration.


How Does the Combination Prevent Conception?

The medication achieves its purpose through a highly effective triple barrier mechanism involving three distinct physiological actions. This systemic approach causes the inhibition of ovulation, meaning the ovaries are suppressed from releasing an egg. Additionally, the progestogen component is responsible for a rapid thickening of cervical mucus, creating a physical barrier hostile to sperm movement, and simultaneously, the medication induces alteration of the endometrium (uterine lining). These combined effects establish a multi-layered, medically supported approach to ensure reliable prevention of pregnancy.

What side effects are possible with Estelle?

The official safety profile for Estelle (Ethinyl Estradiol/Levonorgestrel) defines potential adverse reactions by their expected frequency and the body system affected, based on regulatory documentation.

Frequency-Classified Adverse Reactions

Adverse effects are grouped to communicate their incidence.

Classification Examples of Documented Effects
Very Common (ge 10%) Headache, irregular/heavy uterine bleeding, nausea/vomiting, breast tenderness.
Common (1%-10%) Mood changes (including depression), abdominal pain, acne, weight changes, dizziness.
Rare (< 0.1%) Anaphylactic reactions, cholestatic jaundice, erythema nodosum.

Side effects are organized into System-Organ Classes, including Vascular Disorders, Nervous System Disorders, Gastrointestinal Disorders, and Reproductive System & Breast Disorders.

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions Regulatory documents emphasize the documented risk of Thromboembolic Disorders, which includes Venous Thromboembolic Events (VTE), Pulmonary Embolism, Stroke, and Myocardial Infarction. Other serious risks include the development of benign or malignant Hepatic Neoplasia and new-onset or exacerbated Hypertension.

Population-Specific Safety Use is contraindicated in specific high-risk populations, most notably females over the age of 35 who smoke, or those with certain types of migraine headaches (with aura). The medication is also contraindicated in individuals with uncontrolled high blood pressure or severe liver disease.

Time-Related Safety Pattern The risk of venous thrombotic events is officially documented as highest during the first year of use. Additionally, irregular bleeding and spotting are most common during the initial first three months of treatment.

Overdose and Emergency Response

Estelle (Ethinyl Estradiol/Levonorgestrel) is a combined hormonal contraceptive with a generally low acute toxicity profile in overdose situations, according to official regulatory data. Authorities indicate that the overdose is typically not likely to be life-threatening, and serious undesirable effects have not been reported following the acute ingestion of large doses.

The officially documented clinical manifestations of overdose are commonly observed in the gastrointestinal and reproductive systems. These include expected symptoms such as Nausea and Vomiting, as well as Vaginal bleeding (withdrawal bleeding), which may occur in women and girls following the acute event. Other documented signs are Headache, Drowsiness, and Breast tenderness. These symptoms are noted to occur in both adults and children who use the medication.

In the event an overdose is suspected, individuals are mandated by regulatory documents to seek medical help right away and immediately call a poison control center for specific guidance on next steps. The treatment for Estelle overdose is confined to symptomatic and supportive treatment because no specific antidote is known. Healthcare providers may utilize measures such as monitoring vital signs and administering Activated charcoal in specific circumstances as part of the supportive care strategy.

Therapeutic Uses of Estelle

What Estelle Treats: Main Uses and Benefits

Estelle is applied across therapeutic domains where additional symptomatic support is needed, primarily as an established method of contraception (pregnancy prevention). This medication is commonly used to help with this goal.

It is commonly used across conditions characterized by periods of heightened symptoms. These uses commonly include addressing excessive menstrual bleeding ( menorrhagia), severe, debilitating menstrual cramping ( dysmenorrhea), and symptoms related to irregular periods, and is also applied in addressing moderate acne vulgaris symptoms and the severe mood changes associated with Premenstrual Dysphoric Disorder ( PMDD).

“This supportive relief may assist with maintaining functional stability and coping more steadily with symptom fluctuations.”

In these clinical settings, the medication contributes to improved comfort during symptomatic periods and may assist patients with managing the overall symptom load related to their monthly cycle.


Quick Fact: Use in Managing Heavy and Painful Periods
Estelle is generally applied when symptoms include excessive menstrual blood loss or severe pain that interferes with daily functioning. This approach is relevant for easing symptom clusters related to physical discomfort.

Regulatory References

  1. NIH MedlinePlus overview of Ethinyl Estradiol and Levonorgestrel

Eligibility and Restrictions for Use

The eligibility profile for Estelle (Ethinyl Estradiol/Levonorgestrel) is strictly defined by regulatory documents, which establish population boundaries based on risk factors. The medicine is indicated for use by females of reproductive potential only, specifically those after menarche. It is not intended for use in postmenopausal women.


Populations for whom use is Contraindicated

Use is contraindicated (absolutely prohibited) for groups with high-risk conditions. This includes women over 35 who smoke cigarettes, due to the increased risk of serious cardiovascular events. Other contraindications involve a history of or current venous or arterial thrombotic diseases (such as DVT, PE, stroke, or heart attack), estrogen-sensitive cancers (e.g., breast cancer), severe liver disease or liver tumors, and known or suspected pregnancy.

Contraindications also apply to individuals with uncontrolled hypertension, diabetes with vascular damage, migraine headaches with aura, and those taking specific Hepatitis C drug combinations.


Restrictions on Use

The medicine is not recommended during lactation. Use is also subject to time-based restrictions: it must be discontinued four weeks prior to major surgery with prolonged immobilization and not initiated until four weeks after delivery in non-nursing women.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Estelle's effectiveness can be impacted by other medicines through alterations in its plasma concentration, primarily via the liver enzyme cytochrome P450 3A4 (CYP3A4).

Contraindicated Combinations (Do Not Use)

  • Other hormonal contraceptives: Estelle must not be used concurrently with any other hormonal contraceptive method.
  • Hepatitis C Antivirals: The coadministration of Estelle with certain antiviral medicines, including combinations containing glecaprevir/pibrentasvir or ombitasvir/paritaprevir/ritonavir and dasabuvir, is contraindicated due to the potential for elevated liver enzyme levels.

Interactions Reducing Efficacy

  • Enzyme Inducers: Medicines that induce hepatic microsomal enzymes (e.g., certain anticonvulsants, antibiotics, and herbal products like St. John’s Wort) can accelerate the breakdown of the hormones in Estelle, potentially reducing its therapeutic effect. An alternative or additional non-hormonal method of contraception is required during treatment with these agents and for a specified period after discontinuation.
  • Broad-Spectrum Antibiotics: Certain antibiotics may interfere with the hormonal components' recirculation in the body, which could decrease contraceptive reliability.

Interactions Increasing Exposure

  • Enzyme Inhibitors: Strong inhibitors of CYP3A4 (e.g., certain antifungals or HIV protease inhibitors) may increase the plasma concentrations of the active hormones, potentially raising the risk of adverse effects. Additionally, Estelle can affect the concentration of other medicines, such as increasing the exposure to cyclosporine or reducing the concentration of lamotrigine.

Mechanism of Action

Central Endocrine Pathway Suppression

The primary mechanism involves the agonist binding of both synthetic hormones to their respective Progesterone ( PR) and Estrogen ( ER) Receptors in the hypothalamus and pituitary gland. This receptor activation establishes a sustained, continuous negative feedback on the Hypothalamic-Pituitary-Ovarian ( HPO) axis. This central endocrine blockade overrides the natural cyclical rhythm, preventing the mid-cycle LH surge and the necessary follicular maturation, which collectively results in the inhibition of ovulation (anovulation).


Peripheral Barrier and Receptivity Modulation

This secondary, complementary domain relies on the direct, localized action of the Levonorgestrel component on peripheral reproductive tissues. The active progestogen acts on the cervix to rapidly alter the secreted mucus, transforming it into a viscous, resistant barrier that impedes cell transit. Concurrently, the hormonal activity induces specific atrophic and structural changes in the endometrial lining, rendering the uterus physiologically unreceptive. These peripheral effects provide a complementary physical and structural reinforcement.


Mechanistic Synergy and Limitations

The combination leverages mechanistic synergy where the estrogen component potentiates the biological activity of the progestogen by inducing SHBG synthesis, which increases Levonorgestrel's duration and systemic presence. The entire mechanism is strictly concentration-dependent. Any factor leading to sub-therapeutic plasma levels—such as malabsorption or increased metabolism by CYP450 enzyme inducers—risks weakening the negative feedback, allowing for follicular escape and the potential resumption of the HPO axis activity.

Dosage and Administration Information

How Estelle is Used

Estelle, a combined oral contraceptive containing Ethinyl Estradiol and Levonorgestrel, is administered orally as a solid tablet. The usage is defined by specific, fixed schedules intended for long-term administration.


Administration and Timing

The fundamental principle of administration is the oral route, with a required dose of one tablet daily taken at the same time every day. This consistency is required to maintain the established pattern of use. Administration may occur without regard to meals.

Dosing Cycles and Sequence

Usage follows specific cyclic patterns:

  • Conventional Cyclic Regimen: This course typically involves 21 consecutive days of active hormone tablets, followed by 7 days of non-hormonal or low-dose estrogen tablets. A withdrawal bleed commonly occurs during this hormone-free interval.
  • Extended-Cycle Regimen: This course typically involves 84 consecutive days of active tablets, followed by 7 days of a low-dose tablet, reducing the frequency of withdrawal bleeding.

Tablets must be taken sequentially in the order directed on the blister packaging to ensure the correct daily pattern of active and inactive hormone intake is followed.

Initiation and Use Patterns

Treatment is initiated using specific protocols, such as a Day 1 Start or Sunday Start. When starting later than Day 1 of the menstrual cycle, instructions mandate the use of an additional non-hormonal method of contraception for the first 7 consecutive days of active tablet use. The drug is indicated exclusively for use by females of reproductive potential.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Estelle

This overview summarizes the structure of the official clinical evidence for Estelle (Ethinyl Estradiol/Levonorgestrel), focusing on what research has been conducted, what outcomes have been measured, and where scientific data remains uncertain. This information is purely descriptive and should not be used for self-diagnosis or to replace a discussion with a healthcare provider.


Evidence for Use in Preventing Pregnancy (Contraception)

Studies for this primary use are derived from large-scale Phase 3 clinical trials and long-term epidemiological studies conducted in women of reproductive potential. Researchers monitored the physiological suppression of ovarian function and measured the pregnancy rate using standardized metrics like the Pearl Index to quantify the rate of contraceptive failure. Reported data allowed for the comparison of outcomes between individuals who adhered strictly to the regimen (perfect use) and those who did not (typical use).

What remains uncertain is the full extent of the difference in reported outcome measurements between the highly controlled clinical trial setting and broader population studies. The research is limited in describing outcomes across certain special populations, such as those with very high Body Mass Index (BMI), meaning the results apply only to the populations studied in the primary trials.


Evidence for Use in Managing Excessive Menstrual Bleeding ( menorrhagia)

This use was evaluated in randomized controlled trials (RCTs) and systematic reviews applied in research contexts involving fluctuating or unstable symptoms. Research examined key outcomes related to physiological strain or stress, specifically the absolute volume of blood loss and the presence of iron deficiency ( anemia) in women diagnosed with objectively heavy menstrual bleeding. The findings described patterns that were associated with patterns of iron status over the follow-up period.

The existing research provides limited insight into how this specific Levonorgestrel combination compares to every other combined pill available, as the evidence quality varies across studies, and many reviews group the findings as a class effect of low-dose combined contraceptives. Follow-up durations were limited in some trials, with primary assessments focused on the first three to six cycles.


Evidence for Symptomatic Support: Acne, Cramping, and PMDD

Research has explored the use of this pill combination for outcomes related to physical discomfort and outcomes linked to inflammatory states in women experiencing conditions involving periods of heightened symptoms.

  • Research on Severe Menstrual Cramping: Short-term RCTs applied in studies examining patient-reported experiences of pain focused on outcomes such as the use of rescue pain medication and changes in pain intensity scores.
  • Research on Symptoms of Moderate Acne: Randomized, controlled clinical trials measured the reduction in the number of acne lesions and used clinician global assessments of skin appearance. Studies generally used an observation period of six months to describe patterns observed.
  • Research on Premenstrual Dysphoric Disorder ( PMDD): Double-blind, placebo-controlled trials utilized validated scales to monitor outcomes capturing phases of heightened symptom activity, including changes in mood and functional impairment. The evidence for PMDD is often derived from trials using specialized, continuous regimens, and data for standard cyclic use may be less extensive.

Key Studies & References

  1. Ethinyl Estradiol and Levonorgestrel: MedlinePlus Drug Information
  2. Management of abnormal uterine bleeding: NICE Clinical Guideline
  3. Effect of oral contraceptives on menstrual pain: A systematic review

Frequently Asked Questions (FAQ)

Common questions about Estelle (FAQ)


Q: How quickly does Estelle start working for its intended purpose?

Official instructions advise that, when initiating use later than the first day of the menstrual cycle, an additional, non-hormonal method of contraception is recommended for the first seven consecutive days of active pill use. This ensures the full establishment of the medication's contraceptive effects.

Q: Is it normal to have spotting when you first start taking Estelle?

Yes, official safety information indicates that irregular vaginal bleeding or spotting is a very common side effect, particularly during the initial first three months of treatment. This spotting is typically reported to lessen as the body adjusts to the hormonal medication, usually within the first few cycles.

Q: Does Estelle affect cholesterol levels?

The official safety profile for this combined oral contraceptive does not explicitly list effects on general blood cholesterol levels as a common or very common side effect. However, due to its systemic hormonal effects, monitoring of metabolic health, including lipid levels, may be part of routine medical care for individuals taking hormonal contraceptives.

Q: Can you take antibiotics while on Estelle?

Some regulatory texts note that certain broad-spectrum antibiotics may potentially interfere with the hormonal components of Estelle, which could reduce contraceptive reliability. If broad-spectrum antibiotics are prescribed, using an additional, non-hormonal barrier method of contraception may be recommended by a healthcare professional for a period of time, as this risk is often managed on a case-by-case basis.

Q: What happens if you miss a dose of Estelle?

Regulatory documents provide detailed, specific instructions for handling a missed dose, which vary based on how many pills were missed and their position in the cycle. In cases where a single active tablet is missed, the general guidance from regulatory information is to take it as soon as it is remembered.

Q: Does Estelle cause weight gain or weight loss?

Clinical trial data notes weight changes as a common side effect of combined oral contraceptives like Estelle. This is a general term indicating that some users have reported either an increase or a decrease in weight.

Q: Can Estelle affect my mood or cause anxiety?

Official adverse reaction reports indicate that mood changes, including depression, have been commonly reported in clinical trials. Some regulatory labels also mention anxiety or panic attacks as a possible side effect that should be discussed with a healthcare provider if persistent.

Q: Is it necessary to take Estelle at the exact same time every day?

Regulatory instructions specify that to maintain the maximum level of effectiveness as supported by clinical research, adherence to a consistent dosing schedule, typically involving a strict 24-hour interval, is required. Consistent timing is critical for ensuring reliable contraceptive efficacy.

Q: Are there any specific foods or drinks to avoid while taking Estelle?

Regulatory warnings advise caution regarding grapefruit or grapefruit juice. Official information suggests these may increase the concentration of the active hormones in your blood by inhibiting specific liver enzymes.

Q: Does Estelle change the length or flow of your period?

The hormonal action of Estelle typically results in a lighter or shorter withdrawal bleed compared to a natural menstrual cycle. Adverse reaction reports confirm that irregular bleeding and spotting are also common, particularly during the initial adjustment period.

Q: What should I do if I get sick (vomiting/diarrhea) while taking Estelle?

If you experience severe vomiting or diarrhea, the pill may not be fully absorbed, which can reduce its effectiveness. If this occurs, a healthcare professional may advise following the general instructions for a missed dose and considering the use of a back-up non-hormonal contraceptive method.

Q: Is it true that Estelle can improve acne?

Yes, this combination of hormones has been clinically studied and has been shown in studies to reduce the number of acne lesions in women with moderate acne. Certain formulations may be specifically indicated for this use in addition to contraception.

Q: Does taking Estelle affect future fertility?

Official regulatory information does not indicate that the use of combined oral contraceptives causes long-term impairment of future fertility after the medication is discontinued. The drug’s action is temporary and reversible.

Q: Is Estelle considered a 'low-dose' pill?

Estelle contains doses of ethinyl estradiol and levonorgestrel that are generally classified within the category of low-dose combined oral contraceptives. This classification refers to the concentration of the estrogen component, which is typically low.

Q: Can Estelle be taken by people who have a history of migraines?

Official product information states that the use of Estelle is contraindicated (prohibited) for women who experience migraine headaches with aura. A comprehensive assessment by a healthcare provider is required for all individuals with a history of migraines.

Q: Can Estelle be used to manage symptoms of PMDD?

This hormone combination has been evaluated in controlled clinical trials, and specific formulations may carry an official indication for the management of Premenstrual Dysphoric Disorder (PMDD) based on positive results from those studies.

Q: Is it normal to feel tired or fatigued after starting Estelle?

Patient drug information sheets and regulatory documents have listed feelings such as 'weakness,' 'lack of energy,' and 'fatigue' as possible side effects. Persistent or severe feelings of fatigue should be discussed with a healthcare provider, as with any ongoing adverse reaction.

Q: Has Estelle been studied in different age groups of women?

Official product information states that the drug is indicated for use exclusively by females of reproductive potential who have already started their menstrual periods (post-menarche). It is not intended for use in pre-pubescent girls or postmenopausal women.

Q: Do you need a specific test before starting Estelle?

Regulatory documents require that a healthcare provider take a complete medical history and perform a physical examination before prescribing Estelle. While specific lab tests are not universally mandated, monitoring may be required for certain conditions, such as checking blood pressure.

Q: How reliable is Estelle if taken perfectly?

Studies for contraceptive effectiveness track outcomes for both perfect use (strict adherence) and typical use (including errors). Regulatory data shows a very high level of effectiveness when the medication is used perfectly as directed, as quantified by the Pearl Index.

Q: Can Estelle be taken during travel across different time zones?

Yes, but regulatory guidance emphasizes the critical need to maintain a consistent dosing interval of no more than 24 hours between active pills. When crossing time zones, this requires careful scheduling to ensure the 24-hour interval is always maintained.

Q: Why do some people experience breast tenderness on Estelle?

Breast tenderness is listed as a very common side effect in clinical trials. This is generally attributed to the hormonal components of the pill, particularly the synthetic estrogen (Ethinyl Estradiol), which can lead to stimulation of breast tissue.

Q: Is there a generic version of Estelle available?

Yes, regulatory records confirm that the active drug components in Estelle (Levonorgestrel and Ethinyl Estradiol) are widely available as approved generic versions from various manufacturers.

Q: Does Estelle reduce the risk of any other health conditions?

Epidemiological evidence cited by health authorities supports that the use of combined oral contraceptives is associated with a reduction in the risk of certain cancers, specifically ovarian cancer and endometrial cancer.

Q: What kind of studies have been done on Estelle?

Official clinical sections describe that studies include large-scale Phase 3 clinical trials for contraceptive effectiveness and randomized controlled trials (RCTs) to assess use for conditions like heavy menstrual bleeding, acne, and PMDD.

Q: What should I tell my dentist or surgeon about Estelle?

It is important to inform all healthcare professionals, including dentists and surgeons, that the medication is being taken. Regulatory warnings specify that the product should be discontinued four weeks prior to major surgery involving prolonged immobilization, due to the documented risk of blood clots.

How should Estelle be stored and disposed of?

Estelle tablets must be stored according to official regulatory specifications to maintain product integrity and stability.

Storage Conditions and Requirements

The medication should be stored in a closed container at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C (86 F). The product must be protected from both freezing and excessive exposure to heat, moisture, and direct light. To maintain stability, the tablets must remain in their original packaging or blister pack until needed.

Handling and Child Safety

Estelle must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Estelle tablets must not be thrown away with regular household trash or flushed down the toilet unless specifically authorized by regulation. The preferred method for discarding unneeded medicine is through a drug take-back program. If this option is unavailable, the product should be mixed with an unappealing substance (like dirt or coffee grounds), sealed in a container, and then placed in the household trash, following established regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Estelle found in:

A-Z Index: